<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823391</url>
  </required_header>
  <id_info>
    <org_study_id>M16-560</org_study_id>
    <secondary_id>2018-003053-21</secondary_id>
    <nct_id>NCT03823391</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 and ABBV-154 in Participants With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 and ABBV-154 in Subjects With Moderate to Severe Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a adalimumab active-controlled study to assess the safety, tolerability,
      pharmacokinetics (PK), pharmacodynamics, immunogenicity and efficacy following multiple
      intravenous (IV) injections of ABBV-3373, multiple IV injections of ABBV-154, or multiple
      subcutaneous (SC) injections of adalimumab in participants with Rheumatoid Arthritis (RA) on
      background methotrexate (MTX). This study will also compare adalimumab with a synthetic
      control arm using historical placebo participants from similar trials to establish assay
      sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">November 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity score (DAS) 28 (C-reactive protein [CRP]) from Baseline (BL)</measure>
    <time_frame>At Week 12</time_frame>
    <description>DAS is a combined index used to measure the disease activity in patients with RA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical disease activity index (CDAI) from BL</measure>
    <time_frame>At Week 12</time_frame>
    <description>The CDAI is a composite index for assessing disease activity based on the swollen/tender joint count along with patient and physician global assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in simplified disease activity index (SDAI) from BL</measure>
    <time_frame>At Week 12</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count, patient and physician global assessment of disease activity and level of C-reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS (28 joints) (DAS28) erythrocyte sedimentation rate (ESR) from BL</measure>
    <time_frame>At Week 12</time_frame>
    <description>The DAS is a combined index used to measure the disease activity in patients with RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a low disease activity (LDA)</measure>
    <time_frame>At Week 12</time_frame>
    <description>Low disease activity is defined as DAS28 (CRP) &lt;= 3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving American College of Rheumatology (ACR) 50</measure>
    <time_frame>At Week 12</time_frame>
    <description>ACR 50 response rate will be determined based on 50% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Visual Analog Scale (VAS)), Patient's Global Assessment of Disease Activity (PtGA), Physician's Global Assessment of Disease Activity (PhGA), Health Assessment Questionnaire Disability Index (HAQ-DI), or high-sensitivity C-reactive protein (hsCRP).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>ABBV-3373 Cohort: ABBV-3373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-3373 dose A and placebo for adalimumab every other week for 12 weeks. After 12 weeks, participants will receive placebo for adalimumab every other week until Week 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-3373 Cohort: Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with placebo for ABBV-3373 and adalimumab dose A every other week for 12 weeks. After 12 weeks, participants will receive adalimumab dose A every other week until Week 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-154 dose A and placebo for adalimumab every other week for 12 weeks. After 12 weeks, participants will receive placebo for adalimumab every other week until Week 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-154 dose B and placebo for adalimumab every other week for 12 weeks. After 12 weeks, participants will receive placebo for adalimumab every other week until Week 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-154 dose C and placebo for adalimumab every other week for 12 weeks. After 12 weeks, participants will receive placebo for adalimumab every other week until Week 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-154 Cohort: Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with placebo for ABBV-154 and adalimumab dose A every other week for 12 weeks. After 12 weeks, participants will receive adalimumab dose A every other week until Week 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-3373</intervention_name>
    <description>ABBV-3373 is administered as intravenous (IV) injection</description>
    <arm_group_label>ABBV-3373 Cohort: ABBV-3373</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-3373</intervention_name>
    <description>Placebo for ABBV-3373 is administered as intravenous (IV) injection</description>
    <arm_group_label>ABBV-3373 Cohort: Adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab is administered as subcutaneous (SC) injection</description>
    <arm_group_label>ABBV-154 Cohort: Adalimumab</arm_group_label>
    <arm_group_label>ABBV-3373 Cohort: Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for adalimumab</intervention_name>
    <description>Placebo for adalimumab is administered as subcutaneous (SC) injection</description>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose A)</arm_group_label>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose B)</arm_group_label>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose C)</arm_group_label>
    <arm_group_label>ABBV-3373 Cohort: ABBV-3373</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-154</intervention_name>
    <description>ABBV-154 is administered as intravenous (IV) injection</description>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose A)</arm_group_label>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose B)</arm_group_label>
    <arm_group_label>ABBV-154 Cohort: ABBV-154 (Dose C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-154</intervention_name>
    <description>Placebo for ABBV-154 is administered as intravenous (IV) injection</description>
    <arm_group_label>ABBV-154 Cohort: Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has the clinical diagnosis of RA for &gt; 3 months based on the 1987 American
             College of Rheumatology (ACR) classification criteria or 2010 ACR/European League
             against Rheumatism (EULAR) criteria.

          -  Participant meets the following disease activity criteria: &gt;= 4 swollen joints (based
             on 28 joint count) and &gt;= 4 tender joints (based on 28 joint count) at Screening and
             Baseline visits and disease activity score (28 joints) (DAS28) C-reactive protein
             (CRP) &gt;= 3.2 at Screening.

          -  ABBV-3373 Cohort: Participant has an incomplete response to MTX. Participants must
             have been on oral or parental MTX therapy &gt;= 3 months and on a stable prescription of
             15 to 25 mg/week (or &gt;= 10 mg/week in participants intolerant of MTX at doses &gt;= 15
             mg/week) for &gt;= 4 weeks prior to the first dose of study drug. Participant must be
             expected to be able to continue on stable dose of MTX for the duration of study
             participation.

          -  ABBV-154 Cohort: Participant has an incomplete response response to prior biologic
             disease-modifying antirheumatic drug (bDMARD)and/or targeted synthetic
             disease-modifying antirheumatic drug (tsDMARD) therapy (Bio-IR). Participant must be
             expected to be able to continue on stable dose of MTX for the duration of study
             participation.

        Exclusion Criteria:

          -  For ABBV-3373 Cohort: Participants previously exposed to adalimumab or other
             anti-tumor necrosis factor (TNF) biologics.

          -  For ABBV-3373 Cohort: Participants previously exposed to non-anti-TNF biologics or
             targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for RA, with
             exception of participants exposed for less than 3 months and terminated not due to
             lack of efficacy or intolerability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheum Assoc of North Alabama /ID# 213626</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 208515</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>C.V. Mehta MD, Med Corporation /ID# 213068</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robin K. Dore MD, Inc /ID# 213045</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Rheum &amp; Osteo Med Grp /ID# 213044</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research /ID# 213973</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, Inc. /ID# 213972</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>W. Broward Rheum Assoc Inc. /ID# 211017</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group, Inc. /ID# 213935</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614-7101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Researc /ID# 213043</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Captain James A. Lovell Federal Health Care Center /ID# 214701</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064-3048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PRN Professional Research Network of Kansas, LLC /ID# 213046</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research /ID# 213921</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC /ID# 215451</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810-2607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joint &amp; Muscle Research Instit /ID# 215453</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Early Phase Research Unit (DCRI) /ID# 213212</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research Con /ID# 209042</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc. /ID# 213933</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45377-9464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Inst /ID# 208838</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>PCCR Solution /ID# 215457</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Research Association /ID# 209167</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024-5283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite Research Organisation GmbH /ID# 210216</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 210055</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>DRC Gyogyszervizsgalo Kozpont Kft. /ID# 210159</name>
      <address>
        <city>Balatonfüred</city>
        <state>Veszprem</state>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz /ID# 208877</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ /ID# 210164</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 212747</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center /ID# 219119</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 211339</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum /ID# 209303</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SANUS Szpital Specjalistyczny /ID# 209022</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Reumatika - Centrum Reumatologii NZOZ /ID# 209220</name>
      <address>
        <city>Warsaw</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC /ID# 208154</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mindful Medical Research /ID# 208403</name>
      <address>
        <city>San Juan</city>
        <zip>00918-3756</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis (RA)</keyword>
  <keyword>ABBV-3373</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>ABBV-154</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

